Astrana Health (NASDAQ:ASTH) Hits New 1-Year Low – Should You Sell?

Astrana Health, Inc. (NASDAQ:ASTH) shares reached a new 52-week low on Thursday . The stock traded as low as $20.72 and last traded at $22.03, with a volume of 751310 shares trading hands. The stock had previously closed at $21.38.

Analysts Set New Price Targets

ASTH has been the topic of a number of research reports. TD Cowen reduced their price target on shares of Astrana Health from $40.00 to $35.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Zacks Research cut Astrana Health from a “hold” rating to a “strong sell” rating in a report on Monday, November 10th. BTIG Research decreased their target price on Astrana Health from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Friday, November 7th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Astrana Health in a research note on Monday. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Astrana Health presently has an average rating of “Hold” and a consensus target price of $45.29.

Astrana Health Stock Performance

The business’s fifty day moving average price is $28.77 and its two-hundred day moving average price is $27.29. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.59 and a current ratio of 1.59. The stock has a market capitalization of $1.27 billion, a P/E ratio of 44.12, a P/E/G ratio of 0.90 and a beta of 0.80.

Astrana Health (NASDAQ:ASTH) last announced its quarterly earnings results on Wednesday, January 10th. The company reported $0.50 EPS for the quarter. The firm had revenue of $317.00 million during the quarter. Astrana Health had a net margin of 1.04% and a return on equity of 3.43%. As a group, sell-side analysts forecast that Astrana Health, Inc. will post 1.15 earnings per share for the current year.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Allianz Asset Management GmbH raised its holdings in Astrana Health by 32.5% during the 1st quarter. Allianz Asset Management GmbH now owns 32,600 shares of the company’s stock valued at $1,011,000 after buying an additional 8,000 shares during the period. Diamond Hill Capital Management Inc. increased its position in Astrana Health by 32.6% during the first quarter. Diamond Hill Capital Management Inc. now owns 211,038 shares of the company’s stock valued at $6,544,000 after acquiring an additional 51,827 shares during the last quarter. Royce & Associates LP increased its position in Astrana Health by 13.8% during the first quarter. Royce & Associates LP now owns 290,707 shares of the company’s stock valued at $9,015,000 after acquiring an additional 35,155 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of Astrana Health in the first quarter valued at $564,000. Finally, Natixis Advisors LLC lifted its holdings in shares of Astrana Health by 14.3% in the 1st quarter. Natixis Advisors LLC now owns 27,622 shares of the company’s stock worth $857,000 after acquiring an additional 3,462 shares during the last quarter. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.